HLA DP DQ DR antibody | WR18










Mouse anti Human HLA DP DQ DR:FITC
Mouse anti Human HLA DP DQ DR
Mouse anti Human HLA DP DQ DR:RPE
Mouse anti Human HLA DP DQ DR:Starbright Blue 700
Mouse anti Human HLA DP DQ DR:Amethyst Orange
Mouse anti Human HLA DP DQ DR:Starbright Violet 440
Mouse anti Human HLA DP DQ DR:Starbright Violet 515
Mouse anti Human HLA DP DQ DR:Starbright Violet 610
Mouse anti Human HLA DP DQ DR:Starbright Violet 670
- Product Type
- Monoclonal Antibody
- Clone
- WR18
- Isotype
- IgG2a
Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|
MCA477F | F | 0.1 mg |
![]() |
|
MCA477 | F FN* P* | 0.2 mg |
![]() |
|
MCA477PE | F | 100 Tests |
![]() |
|
MCA477SBB700 | F | 100 Tests/0.5ml |
![]() |
|
MCA477AMO | F | 0.1 mg |
![]() |
|
MCA477SBV440 | F | 100 Tests/0.5ml |
![]() |
|
MCA477SBV515 | F | 100 Tests/0.5ml |
![]() |
|
MCA477SBV610 | F | 100 Tests/0.5ml |
![]() |
|
MCA477SBV670 | F | 100 Tests/0.5ml |
![]() |
The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In humans, this complex is referred to as the human leukocyte antigen (HLA) region. There are 3 major MHC class II proteins encoded by the HLA which are HLA DP, HLA DQ and HLA DR.
Product Details
- Target Species
- Human
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to StarBright Blue 700 - liquid
- Product Form
- Purified IgG conjugated to Amethyst Orange - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 440 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 515 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 610 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 670 - liquid
- Reconstitution
- Reconstitute with 1 ml distilled water
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Immunogen
- Human HLA Class II (DP, DQ, DR).
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells from NS0 mouse myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C or at -20°C if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Regulatory
- For research purposes only
Applications of HLA DP DQ DR antibody
Application Name | Verified | Min Dilution | Max Dilution |
---|---|---|---|
Flow Cytometry | Neat | 1/10 | |
Flow Cytometry | 1/50 | 1/200 | |
Functional Assays 1 | |||
Immunohistology - Paraffin 2 | |||
Flow Cytometry | Neat | ||
Flow Cytometry | Neat | ||
Flow Cytometry | Neat | ||
Flow Cytometry | Neat | ||
Flow Cytometry | Neat | ||
Flow Cytometry | Neat | ||
Flow Cytometry | Neat |
- 1 This product contains sodium azide, removal by dialysis is recommended prior to use in functional assays.
- 2This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Histology Positive Control Tissue
- Tonsil
Secondary Antibodies Available
Negative Isotype Controls Available
Description | Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|---|
Mouse IgG2a Negative Control:FITC | MCA929F | F | 100 Tests |
![]() |
|
Mouse IgG2a Negative Control | MCA929 | F | 100 Tests |
![]() |
|
Mouse IgG2a Negative Control:RPE | MCA929PE | F | 100 Tests |
![]() |
Useful Reagents Available
Description | Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|---|
Human Seroblock | BUF070A | F | 50 Test | ||
Human Seroblock | BUF070B | F | 200 Test | ||
Human Seroblock | BUF070A | F | 50 Test | ||
Human Seroblock | BUF070B | F | 200 Test | ||
Human Seroblock | BUF070A | F | 50 Test | ||
Human Seroblock | BUF070B | F | 200 Test | ||
Human Seroblock | BUF070A | F | 50 Test | ||
Human Seroblock | BUF070B | F | 200 Test | ||
Human Seroblock | BUF070A | F | 50 Test | ||
Human Seroblock | BUF070B | F | 200 Test | ||
Human Seroblock | BUF070A | F | 50 Test | ||
Human Seroblock | BUF070B | F | 200 Test | ||
Human Seroblock | BUF070A | F | 50 Test | ||
Human Seroblock | BUF070B | F | 200 Test | ||
Human Seroblock | BUF070A | F | 50 Test | ||
Human Seroblock | BUF070B | F | 200 Test |
Product Specific References
References for HLA DP DQ DR antibody
-
Moore, K. et al. (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy.
J Pathol 152:13-21. -
Kissner, T.L. et al. (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules.
PLoS One. 6: e15985. -
Chia, J.S. et al. (2001) Human T-cell responses to the glucosyltransferases of Streptococcus mutans.
Clin Diagn Lab Immunol. 8: 441-5. -
Chang, Y.C. et al. (2008) Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.
Blood. 111: 5054-63. -
Litzinger, M.T. et al. (2009) Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Cancer Immunol Immunother. 58: 955-65. -
Sadallah, S. et al. (2011) Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells.
J Immunol. 186: 6543-52. -
Sabbah, S. et al. (2012) T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells.
Blood. 119 (9): 2083-92. -
John, J. et al. (2010) Differential effects of Paclitaxel on dendritic cell function.
BMC Immunol. 11:14. -
Palmer, K.J. et al. (2000) Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC).
Clin Exp Immunol. 119: 412-8. -
Silk, K.M. et al. (2012) Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.
J Biomed Biotechnol. 2012: 172420. -
Elias, F. et al. (2003) Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs.
J Immunol. 171: 3697-704. -
Silk, K.M. et al. (2012) Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells.
Gene Ther. 19 (10): 1035-40. -
Adamski, J. (2004) 17{beta}-Estradiol Inhibits Class II MHC Expression: Influence on Histone Modifications and CBP Recruitment to the Class II MHC Promoter
Molecular Endocrinology 18:1963 -
Keating, S. et al. (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.
J Virol. 76: 8179-88. -
Trefzer, U. et al. (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma.
Int J Cancer. 85 (5): 618-26. -
Hayman, M.W. et al. (2006) Soluble human leukocyte antigen: a diagnostic indicator of rheumatoid arthritis?
J Immunol Methods. 315 (1-2): 19-26. -
Manna, D. et al. (2012) WR18 MONOCLONAL ANTIBODY: A SINGLE ANTIBODY TO DETECT HLA DR, DP AND DQ ANTIGENS.
Abstracts/Human immunology 73:49-167 abstract 36P -
Neumann, F. et al. (2004) Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes.
Cancer Immunol Immunother. 53 (7): 589-99. -
Neumann F et al. (2004) Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
Int J Cancer. 112 (4): 661-8. -
Iking-Konert C et al. (2005) Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells.
Ann Rheum Dis. 64 (10): 1436-42. -
Hönger, G. et al. (2015) Inter-individual differences in HLA expression can impact the CDC crossmatch.
Tissue Antigens. 85 (4): 260-6. -
del Pilar Martin, M. et al. (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
Arch Neurol. 65 (12): 1596-603. -
Noble, P. et al. (2013) High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival.
Br J Cancer. 108 (10): 2097-105. -
Llewelyn, M. et al. (2004) HLA class II polymorphisms determine responses to bacterial superantigens.
J Immunol. 172 (3): 1719-26. -
Koschwanez, H. et al. (2015) Stress-related changes to immune cells in the skin prior to wounding may impair subsequent healing.
Brain Behav Immun. 50: 47-51. -
Ziegler, C.G.K. et al. (2019) Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia.
Cell Rep. 28 (4): 923-937.e3.
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸
How to Use the Spectraviewer?
Watch the Tool Tutorial Video ▸
- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra